Results 41 to 50 of about 7,825,369 (248)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

BMC Neurology, 2012
Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because they release large amounts of various mediators that ...
Vermersch Patrick, Benrabah Rabah, Schmidt Nicolas, Zéphir Hélène, Clavelou Pierre, Vongsouthi Cyrille, Dubreuil Patrice, Moussy Alain, Hermine Olivier   +8 more
doaj   +1 more source

Consensus on early detection of disease progression in patients with multiple sclerosis

Frontiers in Neurology, 2022
BackgroundEarly identification of the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) can be challenging for clinicians, as diagnostic criteria for SPMS are primarily based on physical disability and a ...
José E. Meca-Lallana, Bonaventura Casanova, Alfredo Rodríguez-Antigüedad, Sara Eichau, Guillermo Izquierdo, Carmen Durán, Jordi Río, Miguel Ángel Hernández, Carmen Calles, José M. Prieto-González, José Ramón Ara, Dionisio F. Uría, Lucienne Costa-Frossard, Antonio García-Merino, Celia Oreja-Guevara   +14 more
doaj   +1 more source

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. [PDF]

, 2018
BackgroundThere is a pressing need for robust longitudinal cohort studies in the modern treatment era of multiple sclerosis.ObjectiveBuild a multiple sclerosis (MS) cohort repository to capture the variability of disability accumulation, as well as ...
Uitdehaag, Bernard M.J., KAPPOS, L. D., Cree, Bruce Ac, Hauser, Stephen L., Chitnis, Tanuja, Cree, Bruce Anthony C.C., Montalban, Xavier, Bove, Riley, Weiner, Howard L, Hauser, Stephen L, Kappos, Ludwig, Khoury, Samia J., Khoury, Samia J, Weiner, Howard L., Tintoré, Mar, SUMMIT Consortium, Naegelin, Yvonne, Uitdehaag, Bernard Mj, Bové, Riley Marie   +18 more
core   +1 more source

New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis

Неврология, нейропсихиатрия, психосоматика, 2021
The process of neurodegeneration in multiple sclerosis (MS) remains an urgent problem of modern neurology; from the point of view of its therapy, it is especially important to identify this condition during the transition to secondary progression.
D. S. Kasatkin, N. V. Khachanova, V. M. Alifirova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaya, E. P. Evdoshenko, S. A. Sivertseva   +8 more
doaj   +1 more source

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. [PDF]

, 2012
BACKGROUND: More than half of patients with multiple sclerosis have progressive disease characterised by accumulating disability. The absence of treatments for progressive multiple sclerosis represents a major unmet clinical need.
Kolappan, Madhan, Thompson, Alan J, Luan, Shi-Lu, Altmann, Daniel R, Crawley, Charles, Compston, Alastair, Patani, Rickie, Scott, Michael A, Du, Ming-Qing, Miller, David H, Michell, Andrew W, Chandran, Siddharthan, Connick, Peter, Webber, Daniel J   +13 more
core   +1 more source

Quantification of cerebral tissue volumes in multiple sclerosis: global and regional analysis [PDF]

, 2006
Brain atrophy has been reported in multiple sclerosis (MS). We addressed the question of GM and WM tissue loss in a large population of 597 patients with multiple sclerosis (MS) compared with 104 control subjects using a fully automated, operator ...
Prinster, Anna
core   +1 more source

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines [PDF]

, 2020
With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS, most current diagnostic and treatment algorithms need revision and updating.
Almahdawi, Akram M., Dahdaleh, Maurice P., Alsaadi, Taoufik M., Inshasi, Jihad Said, Yamout, Bassem I., Bohlega, Saeed A., Al-Jumah, Mohammed A., Alsharoqi, Isa Ahmed, Koussa, Salam F., AlKhawajah, Mona Marwan, Al Khaburi, J., Alroughani, Raed A., Goueider, Riyad, Khoury, Samia J., Sahraian, Mohammad Ali, Daodi, S., Slassi, E., Zakaria, Magd Fouad, Hashem, Saher S.   +18 more
core   +1 more source

Optimization of therapy in secondary progressive multiple sclerosis

Неврология, нейропсихиатрия, психосоматика
The article provides an analysis of modern methods of treatment of secondary progressive multiple sclerosis (SPMS). The only drug that has proven its effectiveness in all types of SPMS (with exacerbations and without exacerbations) is siponimod. Clinical
A. N. Boyko, S. K. Zyryanov, Ya. V. Vlasov   +2 more
doaj   +1 more source

Analysis of the time to sustained progression in Multiple Sclerosis using generalised linear and additive models [PDF]

, 2003
The course of multiple sclerosis (MS) is generally difficult to predict. This is due to the great inter-individual variability with respect to symptoms and disability status.
Hellriegel, B., Neiss, A., Neiss, Albrecht, Hellriegel, Barbara, Gehrmann, U., Fahrmeir, Ludwig   +5 more
core   +1 more source

Experience of Identity Change in People Who Reported a Diagnosis of Multiple Sclerosis : A Qualitative Inquiry [PDF]

, 2019
Background: A diagnosis of multiple sclerosis (MS) can lead to changes to a person’s sense of self. The aim of this study was to investigate the subjective experience of identity change and subsequent adjustment to MS.
das Nair, Roshan, Smale, Kathryn, Lincoln, NB, Lincoln, Nadina B., Barker, AB, Hunt, N, Smale, K., das Nair, R, Hunt, Nigel, Barker, Alexander B., Barker, A., Smale, K, Lincoln, N.B., Hunt, N.   +13 more
core   +1 more source